Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

RemeGen Announces Positive Results for HER2 ADC in Urothelial Cancer

publication date: Jun 7, 2019

RemeGen, a Yantai biologics company, reported its HER2-targeting antibody-drug conjugate produced a 51% objective response rate in a China Phase II trial of patients with HER2-positive urothelial cancer. The candidate, RC48, was developed to treat HER2-positive solid tumors. It includes a novel HER2-monoclonal antibody, a cathepsin cleavable linker and a cytotoxic payload. Compared to the current standard of care, the monoclonal antibody has a higher affinity for HER2 and, in animal models, showed higher anti-tumor activity. RemeGen said RC48 is the first ADC drug approved in China for human clinical trials. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital